These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 34022528)

  • 1. Discovery of novel modulators for the PPARα (peroxisome proliferator activated receptor α): Potential therapies for nonalcoholic fatty liver disease.
    Yu DD; Van Citters G; Li H; Stoltz BM; Forman BM
    Bioorg Med Chem; 2021 Jul; 41():116193. PubMed ID: 34022528
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Monascin and ankaflavin act as natural AMPK activators with PPARα agonist activity to down-regulate nonalcoholic steatohepatitis in high-fat diet-fed C57BL/6 mice.
    Hsu WH; Chen TH; Lee BH; Hsu YW; Pan TM
    Food Chem Toxicol; 2014 Feb; 64():94-103. PubMed ID: 24275089
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PPARα/γ agonists and antagonists differently affect hepatic lipid metabolism, oxidative stress and inflammatory cytokine production in steatohepatitic rats.
    Zhang Y; Cui Y; Wang XL; Shang X; Qi ZG; Xue J; Zhao X; Deng M; Xie ML
    Cytokine; 2015 Sep; 75(1):127-35. PubMed ID: 26194065
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Singular effects of PPAR agonists on nonalcoholic fatty liver disease of diet-induced obese mice.
    Barbosa-da-Silva S; Souza-Mello V; Magliano DC; Marinho Tde S; Aguila MB; Mandarim-de-Lacerda CA
    Life Sci; 2015 Apr; 127():73-81. PubMed ID: 25748419
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Silybin alleviates hepatic lipid accumulation in methionine-choline deficient diet-induced nonalcoholic fatty liver disease in mice via peroxisome proliferator-activated receptor α.
    Cui S; Pan XJ; Ge CL; Guo YT; Zhang PF; Yan TT; Zhou JY; He QX; Cheng LH; Wang GJ; Hao HP; Wang H
    Chin J Nat Med; 2021 Jun; 19(6):401-411. PubMed ID: 34092291
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intestinal peroxisome proliferator-activated receptor α-fatty acid-binding protein 1 axis modulates nonalcoholic steatohepatitis.
    Yan T; Luo Y; Yan N; Hamada K; Zhao N; Xia Y; Wang P; Zhao C; Qi D; Yang S; Sun L; Cai J; Wang Q; Jiang C; Gavrilova O; Krausz KW; Patel DP; Yu X; Wu X; Hao H; Liu W; Qu A; Gonzalez FJ
    Hepatology; 2023 Jan; 77(1):239-255. PubMed ID: 35460276
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Integrative study of diet-induced mouse models of NAFLD identifies PPARα as a sexually dimorphic drug target.
    Smati S; Polizzi A; Fougerat A; Ellero-Simatos S; Blum Y; Lippi Y; Régnier M; Laroyenne A; Huillet M; Arif M; Zhang C; Lasserre F; Marrot A; Al Saati T; Wan J; Sommer C; Naylies C; Batut A; Lukowicz C; Fougeray T; Tramunt B; Dubot P; Smith L; Bertrand-Michel J; Hennuyer N; Pradere JP; Staels B; Burcelin R; Lenfant F; Arnal JF; Levade T; Gamet-Payrastre L; Lagarrigue S; Loiseau N; Lotersztajn S; Postic C; Wahli W; Bureau C; Guillaume M; Mardinoglu A; Montagner A; Gourdy P; Guillou H
    Gut; 2022 Apr; 71(4):807-821. PubMed ID: 33903148
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Down-regulation of hepatic CLOCK by PPARα is involved in inhibition of NAFLD.
    Luo J; Yan Z; Dai M; Xu L; Zhang H; Xi Y; Yang J; Liu A
    J Mol Med (Berl); 2023 Feb; 101(1-2):139-149. PubMed ID: 36527474
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Folic acid attenuates high-fat diet-induced steatohepatitis
    Xin FZ; Zhao ZH; Zhang RN; Pan Q; Gong ZZ; Sun C; Fan JG
    World J Gastroenterol; 2020 May; 26(18):2203-2220. PubMed ID: 32476787
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and mechanism of action of Yanxiao Di'naer formula for non-alcoholic steatohepatitis treatment based on metabolomics and RNA sequencing.
    Zheng DX; Hou Q; Xue TT; Gao X; Geng RY; Wen LM; Wang Z; Yin Q; Yin HL; Hu JP; Yang JH
    J Ethnopharmacol; 2024 Oct; 333():118487. PubMed ID: 38925322
    [TBL] [Abstract][Full Text] [Related]  

  • 11. LB100 ameliorates nonalcoholic fatty liver disease
    Chen XY; Cai CZ; Yu ML; Feng ZM; Zhang YW; Liu PH; Zeng H; Yu CH
    World J Gastroenterol; 2019 Dec; 25(45):6607-6618. PubMed ID: 31832001
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Peroxisome proliferator-activated receptor-alpha gene level differently affects lipid metabolism and inflammation in apolipoprotein E2 knock-in mice.
    Lalloyer F; Wouters K; Baron M; Caron S; Vallez E; Vanhoutte J; Baugé E; Shiri-Sverdlov R; Hofker M; Staels B; Tailleux A
    Arterioscler Thromb Vasc Biol; 2011 Jul; 31(7):1573-9. PubMed ID: 21474829
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Peroxisome proliferator-activated receptor-α agonist, Wy 14,643, improves metabolic indices, steatosis and ballooning in diabetic mice with non-alcoholic steatohepatitis.
    Larter CZ; Yeh MM; Van Rooyen DM; Brooling J; Ghatora K; Farrell GC
    J Gastroenterol Hepatol; 2012 Feb; 27(2):341-50. PubMed ID: 21929649
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selective peroxisome proliferator-activated receptor-α modulator K-877 efficiently activates the peroxisome proliferator-activated receptor-α pathway and improves lipid metabolism in mice.
    Takei K; Han SI; Murayama Y; Satoh A; Oikawa F; Ohno H; Osaki Y; Matsuzaka T; Sekiya M; Iwasaki H; Yatoh S; Yahagi N; Suzuki H; Yamada N; Nakagawa Y; Shimano H
    J Diabetes Investig; 2017 Jul; 8(4):446-452. PubMed ID: 28084058
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatoprotective effects of ZLY16, a dual peroxisome proliferator-activated receptor α/δ agonist, in rodent model of nonalcoholic steatohepatitis.
    Zhou Z; Deng L; Hu L; Ren Q; Cai Z; Wang B; Li Z; Zhang L
    Eur J Pharmacol; 2020 Sep; 882():173300. PubMed ID: 32592770
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hypoxia exacerbates nonalcoholic fatty liver disease via the HIF-2α/PPARα pathway.
    Chen J; Chen J; Fu H; Li Y; Wang L; Luo S; Lu H
    Am J Physiol Endocrinol Metab; 2019 Oct; 317(4):E710-E722. PubMed ID: 31430204
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sodium Butyrate Ameliorates High-Fat-Diet-Induced Non-alcoholic Fatty Liver Disease through Peroxisome Proliferator-Activated Receptor α-Mediated Activation of β Oxidation and Suppression of Inflammation.
    Sun B; Jia Y; Hong J; Sun Q; Gao S; Hu Y; Zhao N; Zhao R
    J Agric Food Chem; 2018 Jul; 66(29):7633-7642. PubMed ID: 29961332
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role and regulation of the peroxisome proliferator activated receptor alpha in human liver.
    Kersten S; Stienstra R
    Biochimie; 2017 May; 136():75-84. PubMed ID: 28077274
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sesamin ameliorates hepatic steatosis and inflammation in rats on a high-fat diet via LXRα and PPARα.
    Zhang R; Yu Y; Hu S; Zhang J; Yang H; Han B; Cheng Y; Luo X
    Nutr Res; 2016 Sep; 36(9):1022-1030. PubMed ID: 27632923
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of Novel Peroxisome Proliferator-Activated Receptor α (PPARα) Agonists by Virtual Screening and Biological Evaluation.
    Dai L; Feng Z; Zha R; Cheng K; Wen X; Sun H; Yuan H
    J Chem Inf Model; 2020 Mar; 60(3):1717-1727. PubMed ID: 32027126
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.